The IRF2BPL Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the IRF2BPL gene has been disrupted in the Jurkat human T-lymphocyte background. This product is supplied as a heterogeneous pool of cells, each carrying targeted gene disruption, enabling loss-of-function studies without clonal selection artifacts. It is an ideal tool for investigating IRF2BPL-dependent transcriptional regulation and signaling dynamics in immune cells.
Jurkat cells are a well-established human T-cell leukemia line (clone E6-1) widely used to study T-cell receptor signaling, cytokine production, and apoptosis. These cells recapitulate key aspects of T-cell activation and programmed cell death, making them a robust model for dissecting pathways relevant to immune function and oncogenesis. The Jurkat background provides a physiologically relevant context for exploring the role of IRF2BPL in T-cell biology.
IRF2BPL encodes a transcriptional corepressor that binds IRF2 and potentiates its repressive function by recruiting histone deacetylases, including HDAC1 and HDAC2, and the NCoR corepressor complex. This repressive activity silences IRF2 target genes, such as those involved in interferon responses. Additionally, IRF2BPL interacts with ??-catenin and the Notch intracellular domain (NICD) to modulate Wnt and Notch signaling outputs, linking it to cell fate decisions. Upstream regulators like WNT3A and DLL4 initiate these cascades, while downstream targets include CCND1, MYC, HES1, BAX, and BCL2. Thus, IRF2BPL integrates multiple pathways by physically associating with key effectors such as ??-catenin and NICD, influencing proliferation and apoptosis.
In the Jurkat T-cell leukemia context, IRF2BPL knockout allows researchers to examine how loss of this corepressor impacts transcriptional programs governing cell growth, survival, and death. Since Jurkat cells are heavily reliant on Wnt/??-catenin and Notch signaling for proliferative and anti-apoptotic signals, disrupting IRF2BPL may alter the balance of downstream gene expression, potentially sensitizing cells to apoptosis or altering cell cycle progression. This model is particularly relevant for exploring the intersection of IRF2BPL function with T-cell leukemia pathogenesis and for testing hypotheses related to its emerging role in neurodevelopmental disorders.
Typical applications include functional studies profiling IRF2BPL-dependent gene expression changes via RNA-seq and RT-qPCR for targets like CCND1, HES1, and BAX; assessing apoptosis and cell cycle by flow cytometry; performing co-immunoprecipitation to validate interactions with IRF2, HDACs, or ??-catenin; and evaluating drug sensitivity, such as to HDAC inhibitors, using cell viability assays. The polyclonal nature ensures that results reflect average population effects, which is advantageous for high-throughput screening and unbiased mechanistic investigations. Researchers can also employ reporter assays (TOP/FOP flash, Notch reporter) to measure pathway activity. For custom solutions or further details, please contact Ascent Research.
